Eton Pharmaceutcials
Eton Pharmaceuticals Inc is an American specialty pharmaceutical enterprise specializing in the research, development, acquisition, and commercialization of innovative pharmaceutical products, proprietary drug formulations, and rare disease therapeutics (including hospital injectables, pediatric liquids, and specialized neurology treatments) approved by the U.S. Food and Drug Administration (FDA). The company focuses on developing and commercializing value-adding pharmaceutical treatments for underserved patient populations and rare pediatric conditions. Its core business operations encompass pharmaceutical product development, FDA regulatory navigation, commercial drug marketing, and strategic licensing partnerships. Revenue is derived directly from the commercial sale of approved specialty pharmaceutical products to hospitals, pharmacies, and healthcare distributors. Eton Pharmaceuticals holds a leading market position in specialty rare disease therapeutics and hospital pharmaceuticals in the United States. The company is headquartered in Deer Park, Illinois, United States, and its common stock trades on the Nasdaq Global Market under the ticker ETON.
2 of the funds FundTelligence covers report a position in Eton Pharmaceutcials.
- Legal name
- ETON PHARMACEUTCIALS INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Eton Pharmaceutcials
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)